An observational study in Regional Anesthesia, Burn and Skin Grafting, sponsored by University of Washington. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-04.
Sponsored by University of Washington · Observational
Skin donor sites in patients undergoing split-thickness skin grafting surgeries can be very painful postoperatively. This site is most often the anterolateral thigh, the pain at which location can traditionally be covered by a fascia iliaca nerve block, although that comes with the disadvantage of losing motor functions in the femoral nerve distribution. The LAM nerve block, which is relatively new, aims to provide analgesia in the distribution of the lateral and anterior femoral cutaneous nerves. In short, this nerve block would decrease the sensation of the anterolateral thigh area without affecting the motor function of the leg. Investigators aim to study the consistency and coverage size of sensation changes by mapping out the area after the block in each patient.
719 studies on the registry are indexed under Burns; 145 are open to participants now.
This study's planned enrollment of 10 is below the median of 55 across 135 observational studies indexed under Burns.
Browse Burns studies →University of Washington is the lead sponsor of 1,397 studies on the registry; 225 are open to participants now.
Of its 154 completed or terminated interventional studies of FDA-regulated products, 132 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients 18 years or older who are undergoing skin grafting surgeries
Exclusion Criteria:
Area of sensory change after nerve block
Time frame: 20 min after nerve block placement
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Washington